What is the 13F Pro Quality Score for VNDA?

13F Pro ranks Vanda Pharmaceuticals Inc. (VNDA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VNDA's current score at https://13fpro.ai/company/VNDA (free sign-up required for the full ranking).

Which hedge funds own the most VNDA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of VNDA include BlackRock,, STATE STREET, AQR CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/VNDA as soon as new 13F filings post.

Where does 13F Pro source VNDA data?

All Vanda Pharmaceuticals Inc. fundamentals and ownership data come directly from SEC EDGAR. Vanda Pharmaceuticals Inc. files with the SEC under CIK 1347178. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VNDA in?

Vanda Pharmaceuticals Inc. (VNDA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VNDA research updated on 13F Pro?

VNDA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Vanda Pharmaceuticals Inc.(VNDA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1347178 VNDA stock profile & AI dashboard →

13F Pro Quality Score

25.6/100

Rank #2,657 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

55.4/100

Profitability

6.7/100

Balance Sheet

3.3/100

Earnings Quality

33.0/100

Free Cash Flow

8.0/100

Institutional Flow

69.7/100

Revenue Scale

24.8/100

Dilution Risk

26.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why VNDA Scores 26/100

exact factor attribution · 2026-09-11

VNDA's composite is driven by revenue growth, held back by profitability and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+1.1 pts

55th pct

Institutional flow

+1.0 pts

70th pct

Shareholder dilution

-1.2 pts

27th pct

Earnings quality

-1.7 pts

33th pct

Earnings growth

-2.3 pts

4th pct

Scale

-3.8 pts

25th pct

Capital efficiency

-4.7 pts

3th pct

Free cash flow

-6.3 pts

8th pct

Profitability

-6.5 pts

7th pct

Latest change (2026-08-06): 25 → 31 · ↑ Profit margin 9→25; ↑ Capital efficiency 9→26

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

VNDA Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Vanda Pharmaceuticals Inc. (VNDA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VNDA at 25.6/100 on a 32-signal composite quality model, placing it at rank #2,657 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (3.3) and profitability (6.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Vanda Pharmaceuticals Inc. reports quarterly revenue of $50.5M, net income of $-62.5M, free cash flow of $-31.3M. Top institutional holders of VNDA by reported 13-F value include BlackRock, STATE STREET, AQR CAPITAL MANAGEMENT, based on the most recent SEC filings. VNDA trades on the Nasdaq exchange and files with the SEC under CIK 1347178. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VNDA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vanda Pharmaceuticals Inc. directly from SEC EDGAR. Vanda Pharmaceuticals Inc.'s 13F Pro composite quality score has ranged between 21 and 59 since 2021, currently 25.6 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about Vanda Pharmaceuticals Inc.

Quirks, history, and lore behind VNDA — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap biopharmaceutical company · listed on Nasdaq · headquartered in Washington, DC · focused on central nervous system and other specialty disorders.
2
The Numbers
Annual revenue in the range of $200–250 million — modest by pharma standards — with a lean commercial operation built around a handful of approved drugs rather than a sprawling pipeline.
3
The History
Founded in the early 2000s by scientists with roots in NIH research, it built its identity around repurposing and studying drugs that larger companies had largely overlooked.
4
The Secret
The company has become a specialist in Non-24-Hour Sleep-Wake Disorder — a rare circadian rhythm condition particularly prevalent among the totally blind — a niche almost no one else pursued.
5
The Lore
Its lead product Hetlioz was the first FDA-approved treatment for Non-24, and the company has fought high-profile legal battles to defend its orphan drug exclusivity against generic challengers.
6
The Giveaway
A DC-based biopharma that owns Hetlioz for sleep disorders and Fanapt for schizophrenia — two very different conditions, one very focused specialty pharma niche-hunter.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$50.5M

Net Income

Q2 2026

$-62.5M

Free Cash Flow

Q2 2026

$-31.3M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+8.7% YoY

$216.1MFY 2025

FY22 $254.4MFY23 $192.6MFY24 $198.8MFY25 $216.1M

Net Income

-1066.5% YoY

$-220.5MFY 2025

FY22 $6.3MFY23 $2.5MFY24 $-18.9MFY25 $-220.5M

Operating Income

-271.8% YoY

$-151.2MFY 2025

FY22 $6.3MFY23 $-14.0MFY24 $-40.7MFY25 $-151.2M

EPS (Diluted)

-1033.3% YoY

$-3.74FY 2025

FY22 $0.11FY23 $0.04FY24 $-0.33FY25 $-3.74

Total Assets

-25.5% YoY

$488.9MFY 2025

FY22 $634.2MFY23 $648.4MFY24 $656.2MFY25 $488.9M

Op. Cash Flow

-594.6% YoY

$-109.4MFY 2025

FY22 $32.0MFY23 $12.8MFY24 $-15.8MFY25 $-109.4M

Free Cash Flow

-579.8% YoY

$-110.4MFY 2025

FY22 $31.3MFY23 $12.4MFY24 $-16.2MFY25 $-110.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$216.1M +8.7%	$198.8M +3.2%	$192.6M -24.3%	$254.4M -5.3%	$268.7M +8.3%	$248.2M
Net Income	$-220.5M -1066.5%	$-18.9M -853.3%	$2.5M -60.0%	$6.3M -81.1%	$33.2M +42.1%	$23.3M
Operating Income	$-151.2M -271.8%	$-40.7M -191.4%	$-14.0M -320.4%	$6.3M -85.0%	$42.2M +54.8%	$27.2M
EPS (Diluted)	$-3.74 -1033.3%	$-0.33 -925.0%	$0.04 -63.6%	$0.11 -81.0%	$0.58 +38.1%	$0.42
Total Assets	$488.9M -25.5%	$656.2M +1.2%	$648.4M +2.2%	$634.2M +6.8%	$593.8M +11.3%	$533.5M
Operating Cash Flow	$-109.4M -594.6%	$-15.8M -223.1%	$12.8M -60.0%	$32.0M -50.2%	$64.2M +24.0%	$51.8M
Free Cash Flow	$-110.4M -579.8%	$-16.2M -230.8%	$12.4M -60.3%	$31.3M -50.8%	$63.7M +27.4%	$50.0M

Get alerted when VNDA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Vanda Pharmaceuticals Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VNDA

BlackRock, Inc.
$46.8M7,653,737 sh
STATE STREET CORP
$21.5M3,516,405 sh
AQR CAPITAL MANAGEMENT LLC
$21.4M3,497,695 sh
RENAISSANCE TECHNOLOGIES LLC
$21.1M3,441,361 sh
VANGUARD CAPITAL MANAGEMENT LLC
$15.4M2,524,040 sh
AIGH Capital Management LLC
$12.5M2,044,169 sh
ACADIAN ASSET MANAGEMENT LLC
$11.7M1,918,063 sh
DIMENSIONAL FUND ADVISORS LP
$10.6M1,727,349 sh
MILLENNIUM MANAGEMENT LLC
$9.8M1,602,813 sh
GEODE CAPITAL MANAGEMENT, LLC
$9.1M1,483,787 sh

Fund	Value	Shares
BlackRock, Inc.	$46.8M	7,653,737
STATE STREET CORP	$21.5M	3,516,405
AQR CAPITAL MANAGEMENT LLC	$21.4M	3,497,695
RENAISSANCE TECHNOLOGIES LLC	$21.1M	3,441,361
VANGUARD CAPITAL MANAGEMENT LLC	$15.4M	2,524,040
AIGH Capital Management LLC	$12.5M	2,044,169
ACADIAN ASSET MANAGEMENT LLC	$11.7M	1,918,063
DIMENSIONAL FUND ADVISORS LP	$10.6M	1,727,349
MILLENNIUM MANAGEMENT LLC	$9.8M	1,602,813
GEODE CAPITAL MANAGEMENT, LLC	$9.1M	1,483,787

Companies Similar to VNDA

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ENTA

ENANTA PHARMACEUTICALS INC

AI score

Similar quality profile · 5 shared holders

Krensavage Asset Management, LLC MARTINGALE ASSET MANAGEMENT L P Susquehanna Portfolio Strategies, LLC

EOLS

Evolus, Inc.

AI score

Similar quality profile · 4 shared holders

Krensavage Asset Management, LLC FULLER & THALER ASSET MANAGEMENT, INC.China Universal Asset Management Co., Ltd.

PTHS

Pelthos Therapeutics Inc.

AI score

Similar quality profile · 2 shared holders

AIGH Capital Management LLC China Universal Asset Management Co., Ltd.

CSTL

CASTLE BIOSCIENCES INC

AI score

Similar quality profile · 5 shared holders

AIGH Capital Management LLC KENNEDY CAPITAL MANAGEMENT LLC China Universal Asset Management Co., Ltd.

INGN

Inogen Inc

AI score

Similar quality profile · 2 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC Monaco Asset Management SAM

ARDX

ARDELYX, INC.

AI score

Similar quality profile · 5 shared holders

AIGH Capital Management LLC Krensavage Asset Management, LLC MARTINGALE ASSET MANAGEMENT L P

NVCR

NovoCure Ltd

AI score

Similar quality profile · 6 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC Susquehanna Portfolio Strategies, LLC SYON CAPITAL LLC

KROS

Keros Therapeutics, Inc.

AI score

Similar quality profile · 6 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC Susquehanna Portfolio Strategies, LLC MARTINGALE ASSET MANAGEMENT L P

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VNDA on your watchlist

Track score changes the day Vanda Pharmaceuticals Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VNDA a good stock to buy?

13F Pro's AI-powered analysis of Vanda Pharmaceuticals Inc. (VNDA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VNDA are available on the VNDA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VNDA is classified as a small company.

Which hedge funds own VNDA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VNDA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Vanda Pharmaceuticals Inc.'s investment landscape.